Responding Effectively to Increased Scrutiny under REACH Webinar

(A Steptoe-Sponsored Event)
January 9, 2013

Click here for access to the recording from this webinar.

Click here to view the slides from this webinar.

Please join Steptoe's REACH team for a complimentary webinar on how to effectively respond to increased scrutiny from the European Chemicals Agency (ECHA).

Panel members from Steptoe's REACH team include:
Date: Wednesday, January 9, 2013
Time: 10:00 a.m. EST/16:00 CET
Duration: 90 minutes

ECHA is assessing REACH registration dossiers and raising doubts about the quality of many of them.  ECHA is also implementing key requirements of the regulation and calling on registrants to check and, if necessary, further amend their dossiers – or face the consequences. 
For example, the regulation calls for public dissemination of so-called Safety Data Sheet (SDS) information.  All registrants were advised to review their dossiers with regard to confidentiality concerns and update them, if appropriate – or risk dissemination of sensitive information.  Separately, ECHA has sent letters to over 500 registrants with potentially non-compliant intermediate registrations, asking them to review their justifications and update their registration dossiers within three months – or face potential enforcement action.  In yet other cases, ECHA has already voided registration where information was incorrectly reported – an action that immediately ends companies lawful sales of these substances.
Further, the CoRAP list has been substantially expanded, and competent authorities in Member States are evaluating the substances included in the CoRAP list for 2012.  This evaluation is expected to result in draft decisions addressed to the registrants of these substances by February 28, 2013, including a request to provide additional data or a recommendation for new regulatory action.
The webinar will answer such questions as: 
  • How do I respond to Quality Observation Letters (QOBLs) from ECHA on registrations?
  • How do I defend intermediates?
  • How can I secure confidentiality under the dissemination rules?
  • What are the implication of CoRAP evaluation and what are the criteria and targets?
CLE credit is pending in AZ, CA, IL, NY, and VA.